Local Prescribing Information (Oncology):
Pertuzumab Trastuzumab Injection [Phesgo] ® - Phesgo PI v2.0 dt. Jan 2022
Atezolizumab Injection [Tecentriq®] - Tecentriq PI v21.0 dt. Mar 2022
Bevacizumab Injection [Avastin® and Syndyma®] - Avastin PI v19. dt. Oct 2021 Cipla | Avastin PI v19.0 dt. Oct 2021 Roche
Obinutuzumab Injection [Gazyva®] - Gazyva PI v15.0 dt. Feb 2022
Trastuzumab for Injection [Herclon™ and Biceltis®] - Herclon PI v13.0 dt. Feb 2021 | Biceltis PI v13.0 dt. Feb 2021
Trastuzumab emtansine for Injection [Kadcyla®] - Kadcyla PI v11.0 dt. Jun 2021
Pertuzumab Injection [Perjeta®] - Perjeta PI v12.0 dt. Mar 2021
Rituximab Injection [Ristova® and Ikgdar®] - Ristova PI v12.0 dt. Jan 2021 | Ikgdar PI v12.0 dt. Jan 2021
Alectinib Capsules [Alecensa®] - Alecensa PI v9.0 dt. Jan 2022
Erlotinib Tablets I.P. [Tarceva®] - Tarceva PI v14.0 Dec 2021
Capecitabine Tablets I.P. [Xeloda®] - Tecentriq PI v21.0 dt. Mar 2022
Safety Update Information for Healthcare Professionals (Oncology):
DHPC Xeloda Important Safety update of PI for Xeloda_DPD deficiency dated 3rd October 2018
DHPC Tecentriq Atezolizumab Injection 1200MG/20ML restriction to Tecentriq 1L Cisplatin-Ineligible mUC Indication dated July 23, 2018
Disclaimer - Kindly note that it takes approximately up to 6 months to implement the revised PI in commercial stocks imported into India after submission to the health authorities. All PIs notified to or approved by the CDSCO are published on this website for all the HCPs prescribing Roche drugs within 10 calendar days.